NCT01287338View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

PHASE2TerminatedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Seasonal Allergic Conjunctivitis to Ragweed
Interventions
DRUG

Olopatadine

low dose

DRUG

Olopatadine

high dose

Trial Locations (1)

Unknown

Cetero Research, Toronto

Sponsors
All Listed Sponsors
lead

Mati Therapeutics Inc.

INDUSTRY

NCT01287338 - A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model. | Biotech Hunter | Biotech Hunter